VHL and neoplasm: In the case of renal tumor development, since deletion of VHL in the mouse is not sufficient to drive renal tumor development [34], it will be interesting to determine whether combined deletion of BAF180 and VHL, the two most frequently mutated tumor suppressors in renal cancer, in the kidney would provoke renal tumor phenotype in vivo.